Jazz Cools On Women’s Health, Sells Unit To Meda
This article was originally published in The Pink Sheet Daily
The sale of an asset portfolio that includes Elsetrin for hot flashes could give Jazz the financial flexibility for another product acquisition.
You may also be interested in...
The Swedish specialty pharma is devoting more resources to its growing respiratory franchise and shifting focus away from other therapeutic areas, including women’s health.
With a highly competitive effective tax rate, half a billion dollars in cash, and access to attractively priced capital, specialty pharma Jazz, itself the subject of takeover rumors, has stepped up its ongoing hunt for late-stage assets.
The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.